Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
$8.56
+4.3%
$7.66
$6.51
$13.27
$9.07M1.6293,117 shs3,057 shs
Biofrontera Inc. stock logo
BFRI
Biofrontera
$0.64
-0.1%
$0.75
$0.60
$2.22
$6.04M0.37918,564 shs160,044 shs
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2.92
-10.7%
$2.90
$1.27
$9.47
$9.37M1.671.29 million shs56,354 shs
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
$0.17
-0.9%
$0.25
$0.15
$2.16
$2.45M2.13761,143 shs935,418 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
+3.44%+6.14%+10.30%+1.00%+6.87%
Biofrontera Inc. stock logo
BFRI
Biofrontera
-0.13%-3.03%-21.06%-37.35%-39.14%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-7.42%-10.98%-10.15%+5.42%-1.35%
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
-0.86%-3.46%-21.41%-60.65%+17,289,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
2.0768 of 5 stars
3.53.00.00.03.30.80.0
Biofrontera Inc. stock logo
BFRI
Biofrontera
2.5871 of 5 stars
3.55.00.00.01.40.01.3
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
1.7219 of 5 stars
0.03.00.00.03.83.30.6
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
3.00
Buy$30.00250.47% Upside
Biofrontera Inc. stock logo
BFRI
Biofrontera
3.00
Buy$2.75330.36% Upside
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00
N/AN/AN/A
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TNFA, CYCN, BFRI, and ADXN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Biofrontera Inc. stock logo
BFRI
Biofrontera
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $2.75
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
$404.10K22.45N/AN/A$1.20 per share7.13
Biofrontera Inc. stock logo
BFRI
Biofrontera
$38.00M0.16N/AN/A$3.16 per share0.20
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2.08M4.50N/AN/A$4.62 per share0.63
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
N/AN/AN/AN/A$7.21 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
-$11.76M-$0.34N/AN/A850.30%-112.43%-77.95%6/2/2025 (Estimated)
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%8/13/2025 (Estimated)
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$5.26M-$1.16N/AN/AN/A-55.32%-48.35%8/5/2025 (Estimated)
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
-$4M-$6.67N/AN/AN/A-180.71%-84.27%N/A

Latest TNFA, CYCN, BFRI, and ADXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/2/2025Q1 2025
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
-$1.4197N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million
5/15/2025Q1 2025
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
N/A-$0.36N/A-$0.36N/AN/A
4/11/2025Q4 2024
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
N/A-$0.66N/A-$0.66N/AN/A
3/4/2025Q4 2024
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A$0.22N/A$0.22N/A$1.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
N/AN/AN/AN/AN/A
Biofrontera Inc. stock logo
BFRI
Biofrontera
N/AN/AN/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/A
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
N/A
4.59
4.59
Biofrontera Inc. stock logo
BFRI
Biofrontera
N/A
1.53
0.94
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A
5.07
5.07
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
N/A
1.72
1.72

Institutional Ownership

CompanyInstitutional Ownership
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
16.14%
Biofrontera Inc. stock logo
BFRI
Biofrontera
10.08%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
75.62%
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
9.64%

Insider Ownership

CompanyInsider Ownership
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
15.00%
Biofrontera Inc. stock logo
BFRI
Biofrontera
1.20%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
34.30%
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
1.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
301.06 million901,000Not Optionable
Biofrontera Inc. stock logo
BFRI
Biofrontera
709.45 million7.73 millionNo Data
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
303.21 million1.73 millionNo Data
TNF Pharmaceuticals, Inc. stock logo
TNFA
TNF Pharmaceuticals
614.18 million2.72 millionN/A

Recent News About These Companies

Financial Contrast: TNF Pharmaceuticals (TNFA) and Its Peers
TNF Pharmaceuticals, Inc. Common Stock
TNF Pharmaceuticals initiates isomyosamine trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Addex Therapeutics stock logo

Addex Therapeutics NASDAQ:ADXN

$8.56 +0.35 (+4.26%)
Closing price 05/27/2025 03:56 PM Eastern
Extended Trading
$8.54 -0.02 (-0.28%)
As of 04:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Biofrontera stock logo

Biofrontera NASDAQ:BFRI

$0.64 0.00 (-0.13%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.64 +0.00 (+0.16%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Cyclerion Therapeutics stock logo

Cyclerion Therapeutics NASDAQ:CYCN

$2.92 -0.35 (-10.70%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$2.90 -0.02 (-0.86%)
As of 08:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

TNF Pharmaceuticals stock logo

TNF Pharmaceuticals NASDAQ:TNFA

$0.17 0.00 (-0.86%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.17 0.00 (-0.52%)
As of 07:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.